Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Lucia Torracca
In this interesting session the role of surgical revascularisation was discussed. The number of CABG procedures has considerably decreased in the last ten years, with a concomitant increase in PCI procedures.
Despite this trend, surgical revascularisation still plays an important role. Looking accurately in the results reported by the randomised trials comparing CABG versus PCI in multivessel disease, most of the enrolled patients have two vessel disease and normal ejection fraction. This selection bias eliminates or reduces the group of patients with triple vessel disease, left main stenosis or low ejection fraction, who benefit most from CABG. On the basis of the data from the literature, surgical revascularisation still remains the treatment of choice for patients with triple vessel disease, left main stenosis and low ejection fraction. The advantage of surgical revascularisation is more pronounced in patients treated by complete arterial revascularisation. The results reported in the literature for different type of grafts show that the use of bilateral internal mammary artery have an important impact on long term survival and freedom from reoperation. The use of technical solutions like the Y graft offer the possibility to revascularise all the coronaries with the use of two mammary grafts, giving patients the best option for a durable operation. The role of complete versus incomplete myocardial revascularisation has been analysed, and data currently available are inconclusive on this topic. New data are necessary to answer to this question. Finally an accurate analysis was done about the role of previous PCI on the results of patients treated by CABG. This revision of the literature clearly shows that patients previously treated by PCI have higher mortality and worse long term results after CABG. The reason of this finding is not clear but is probably related to the activation of an inflammatory process by the PCI procedure.
In conclusion, surgical revascularisation, possibly performed by the use of bilateral mammary artery, still remains the treatment of choice in patients with triple vessel disease, left main stenosis and low ejection fraction. The awareness that previous PCI represents a risk factor for patients treated with CABG might be a stimulus for a more accurate selection of patients at their first treatment of coronary artery disease.
Burning questions in coronary revascularisation Symposium
© 2017 European Society of Cardiology. All rights reserved